{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:39:20Z","timestamp":1787927960068,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd010429.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000}}],"reference-count":103,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010429.pub3","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:12:25Z","timestamp":1683724345000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment for osteoporosis in people with beta-thalassaemia"],"prefix":"10.1002","volume":"2023","author":[{"given":"Amit","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics; Sengkang General Hospital; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Mon Min","family":"Swe","sequence":"additional","affiliation":[{"name":"Department of Population Medicine; University Tunku Abdul Raman; Kajang Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal K","family":"Sinha","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics; Manipal University College Malaysia (MUCM); Melaka Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"10.1002\/14651858.CD010429.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.bone.2012.02.478","article-title":"Neridronate improves bone mineral density and reduces pain in beta-thalassemia patients with osteoporosis: Results from a randomized, open-label study","volume":"50","author":"Forni","year":"2012","journal-title":"Bone"},{"issue":"21","key":"10.1002\/14651858.CD010429.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/blood.V116.21.4282.4282","article-title":"Neridronate (NE) for the treatment of osteoporosis in patients with beta-thalassemia: results from an Italian multicenter randomized, open label, phase II trial","volume":"116","author":"Forni","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","article-title":"Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized parallel-arm, open-label study","volume":"158","author":"Forni","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0004|cit4","unstructured":"Efficacy and safety of neridronate (nerixia\u00ae) to treat osteoporosis in patients with TM and TI www.clinicaltrials.gov\/show\/NCT01140321"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3945\/ajcn.112.049221","article-title":"Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial","volume":"98","author":"Fung","year":"2013","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0006|cit6","unstructured":"Zinc & bone health in thalassemia: the think zinc study clinicaltrials.gov\/show\/NCT00459732"},{"issue":"8","key":"10.1002\/14651858.CD010429.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s001980200087","article-title":"Bisphosphonates in the treatment of thalassemia-induced osteoporosis","volume":"13","author":"Morabito","year":"2002","journal-title":"Osteoporosis International"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD010429.pub3-BIB0008|cit8","first-page":"S248","article-title":"Bone mass and bone turnover in women with thalassemia major related osteoporosis: Effects of strontium ranelate","volume":"26","author":"Catalano","year":"2015","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00774-015-0689-8","article-title":"Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis","volume":"34","author":"Morabito","year":"2016","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010429.pub3-BIB0010|cit10","first-page":"S205","article-title":"Effect of pamidronate on bone remodeling in adult patients with beta-thalassemia major and osteoporosis","volume":"5","author":"Voskaridou","year":"2003","journal-title":"Bone"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0011|cit11","unstructured":"Voskaridou E Terpos E Spina G Palermos J Rahemtulla A Loutradi A Pamidronate is an effective treatment for osteoporosis in patients with thalassemia major 8th Congress of the European Hematology Association; 2003 June 12-15; Lyon, France 2003"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0012|cit12","unstructured":"This study investigates the effect of denosumab treatment compared to treatment with placebo, in patients with thalasemia major and osteoporosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-000931-18-GR"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0013|cit13","unstructured":"Denosumab vs placebo in patients with thalassemia major and osteoporosis www.clinicaltrials.gov\/show\/NCT02559648"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/16078454.2019.1570617","article-title":"Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis","volume":"24","author":"Voskaridou","year":"2019","journal-title":"Hematology"},{"issue":"21","key":"10.1002\/14651858.CD010429.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/bloodadvances.2018023085","article-title":"Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial","volume":"2","author":"Voskaridou","year":"2018","journal-title":"Blood Advances"},{"issue":"S1","key":"10.1002\/14651858.CD010429.pub3-BIB0016|cit16","first-page":"333","article-title":"Denosumab effects on serum levels of the bone morphogenic proteins antagonist noggin in patients with beta-thalassemia major and osteoporosis","volume":"2","author":"Voskaridou","year":"2018","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0017|cit17","first-page":"16","article-title":"Denosumab increases bone mineral density in patients with thalassemia major and osteoporosis: results of a randomized, placebo-controlled, double blind, phase 2B clinical trial","volume":"102","author":"Voskaridou","year":"2017","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"Abstract no: 10","DOI":"10.1182\/blood.V120.21.1029.1029","article-title":"The effect of vitamin D supplementation on calcium excretion in thalassemia [abstract]","volume":"120","author":"Balachandar","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000204084","article-title":"Effects of calcitonin therapy on osteoporosis in patients","volume":"93","author":"Canatan","year":"1995","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bmt.2008.414","article-title":"Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients","volume":"44","author":"Chae","year":"2009","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.12048","article-title":"Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome","volume":"159","author":"Chatterjee","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5455\/medarh.2018.72.170-173","article-title":"Administration of intravenous zoledronic acid every 3 Months versus annually in \u03b2-thalassemia patients with low bone mineral density: a retrospective comparison of efficacy","volume":"72","author":"Darvishi-Khezri","year":"2018","journal-title":"Medical Archives"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00223-006-0314-x","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia","volume":"79","author":"Gilfillan","year":"2006","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0024|cit24","unstructured":"Gurkan EG Evran M Tuli A Baslamisli F Kilinc Y Effect of zoledronic acid on the osteoporosis of thalassemia Proceedings of the 10th Congress of the European Hematology Association; 2005 June 2-5; Stockholm International Fairs, Sweden 2005"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02917329","article-title":"A study on children's condition thalassemia using neutron activation analysis and other techniques","volume":"43","author":"Krishnan","year":"1994","journal-title":"Biological Trace Elements Research"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12288-018-0953-x","article-title":"Zoledronic acid for treatment of low bone mineral density in patients with beta thalassemia major","volume":"34","author":"Naithani","year":"2018","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.34172\/ipp.2022.xx","article-title":"Effect of low dose pamidronate in the treatment of thalassemia-induced osteoporosis","volume":"x","author":"Noroozi","year":"2022","journal-title":"Immunopathologia Persa"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0028|cit28","first-page":"882","article-title":"Osteoporosis in thalassemia patients and use of zoledronic acid in the treatment of osteoporosis","volume":"44","author":"Olgun","year":"2019","journal-title":"Cukurova Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00277-006-0136-y","article-title":"Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial","volume":"85","author":"Otrock","year":"2006","journal-title":"Annals of Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010429.pub3-BIB0030|cit30","first-page":"10","article-title":"Intravenous zoledronic acid treatment in thalassaemia-induced osteoporosis: results of a phase two clinical trial [abstract]","volume":"91","author":"Taher","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00774-003-0435-5","article-title":"Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis","volume":"21","author":"Pennisi","year":"2003","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0032|cit32","first-page":"144","article-title":"Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major","volume":"6 Suppl 1","author":"Skordis","year":"2008","journal-title":"Pediatric Endocrinology Reviews: PER"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0033|cit33","first-page":"342","article-title":"Zoledronic acid increases bone mineral density in patients with thalassemia intermedia-induced osteoporosis despite the continuous bone marrow expansion","volume":"92 Suppl 1","author":"Voskaridou","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD010429.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood.V110.11.3813.3813","article-title":"Zoledronic acid increases bone mineral density in patients with thalassemia intermedia-induced osteoporosis regardless of the incessant bone marrow expansion","volume":"110","author":"Voskaridou","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000114869","article-title":"Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis","volume":"119","author":"Voskaridou","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0036|cit36","unstructured":"Evaluation of efficacy of zoledronic acid in patients with haemoglobin syndromes (thalassemia and sicle cell anaemia) and risk of skeletal events clinicaltrials.gov\/show\/NCT00346242"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub3-BIB0037|cit37","first-page":"1193","article-title":"Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"issue":"10","key":"10.1002\/14651858.CD010429.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3324\/haematol.12849","article-title":"Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial","volume":"93","author":"Voskaridou","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD010429.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.V110.11.2768.2768","article-title":"Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow- up of a randomized, placebo-controlled trial","volume":"110","author":"Voskaridou","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD010429.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood.V112.11.3889.3889","article-title":"Serum Dickkopf-1 is increased and correlates with bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration","volume":"112","author":"Voskaridou","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0041|cit41","first-page":"63","article-title":"Serum sclerostin correlates with bone mineral density in patients with thalassemia major and osteoporosis; implications into the management of thalassemia-related osteoporosis","volume":"96","author":"Voskaridou","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD010429.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood.V116.21.1010.1010","article-title":"High circulating levels of sclerostin correlate with bone mineral density in patients with thalassemia and osteoporosis: the role of the WNT signaling in the pathogenesis of bone loss in thalassemia","volume":"116","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010429.pub3-BIB0043|cit43","first-page":"173","article-title":"TIMP-1 balance effect on elevated MMP-9 in patients with thalassemia major and osteoporosis","volume":"96","author":"Voskaridou","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD010429.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1055\/s-0032-1312618","article-title":"High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density","volume":"44","author":"Voskaridou","year":"2012","journal-title":"Hormone and Metabolic Research"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3324\/haematol.2008.000893","article-title":"Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration","volume":"94","author":"Voskaridou","year":"2009","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010429.pub3-BIB0046|cit46","first-page":"357","article-title":"Serum dickkopf-1 is increased and correlates with bone mineral density in patients with thalassemia-induced osteoporosis reduction post zoledronic acid administration","volume":"93","author":"Voskaridou","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD010429.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1182\/blood.V106.11.3656.3656","article-title":"Zoledronic acid is an effective treatment for osteoporosis in patients with thalassemia major: results of a randomized, placebo-controlled, trial","volume":"106","author":"Voskaridou","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0048|cit48","unstructured":"Denosumab versus zoledronic acid in thalassemia-induced osteoporosis www.clinicaltrials.gov\/show\/NCT03040765"},{"issue":"51","key":"10.1002\/14651858.CD010429.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e23637","DOI":"10.1097\/MD.0000000000023637","article-title":"Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis","volume":"99","author":"Yassin","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/09593985.2019.1625089","article-title":"Effect of whole body vibration training on bone mineral density and functional capacity in children with thalassemia","volume":"37","author":"Eid","year":"2021","journal-title":"Physiotherapy Theory and Practice"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0051|cit51","unstructured":"Effect of whole body vibration training on bone mineral density and functional capacity in children with thalassemia trialsearch.who.int\/Trial2.aspx?TrialID=PACTR201804003248173"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0052|cit52","unstructured":"Effects of melatonin on bone metabolism in thalassemia patients with low bone mineral density (randomized controlled study) trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20201223008"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0053|cit53","unstructured":"Trial to study the role of zoledronate in the prevention of early bone loss in patients undergoing bone marrow transplant. in prevention of early bone loss in patients undergoing bone marrow transplant trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2019\/04\/018764"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0054|cit54","unstructured":"Evaluation of intravenous pamidronate & oral alendronate on bone marrow density in patients with major and intermedia thalassemia trialsearch.who.int\/Trial2.aspx?TrialID=IRCT2017070420258N51"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0055|cit55","unstructured":"Zoledronic acid for the prevention of bone loss post-bone marrow transplantation for thalassemia major patients clinicaltrials.gov\/show\/NCT01016093"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.HS9.0000561432.83737.6c","article-title":"The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial","volume":"3 Suppl 1","author":"Piriyakhuntorn","year":"2019","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0057|cit57","unstructured":"Piriyakhuntorn P Tantiworawit A Phimphilai M Srichairatanakool S Teeyasoontranon W Rattanathammethee T The efficacy of alendronate for treatment of thalassemia-associated osteoporosis: a randomized controlled trial 35th Annual Meeting The Royal College of Physicians of Thailand. Towards better and safer patient care; 2019 April 25 - 27; PEACH Royal Cliff Beach Resort, Pattaya, Chonburi, Thailand 2019"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0058|cit58","unstructured":"Efficacy of alendronate in treatment of thalassemia-associated osteoporosis: a randomized controlled trial trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20180219004"},{"issue":"9","key":"10.1002\/14651858.CD010429.pub3-BIB0059|cit59","first-page":"657","article-title":"New\u00a0approaches\u00a0to\u00a0pharmacological treatment\u00a0of\u00a0osteoporosis","volume":"81","author":"Akesson","year":"2003","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jcp.47.7.657","article-title":"Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one or desferrioxamine","volume":"47","author":"Al-Refaie","year":"1994","journal-title":"Journal of Clinical Pathology"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2265.1995.tb01876.x","article-title":"The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches","volume":"42","author":"Kastanias","year":"1995","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1749-6632.1998.tb10482.x","article-title":"Global epidemiology of hemoglobin disorders","volume":"850","author":"Angastiniotis","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.2830240203","article-title":"Effect of zinc supplementation on linear growth in thalassaemia","volume":"24","author":"Arcasoy","year":"1987","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with \u03b2-thalassaemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormones"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0065|cit65","first-page":"196","article-title":"Fractures in transfusion dependent beta thalassemia \u2013 an Indian study","volume":"42","author":"Basanagoudar","year":"2001","journal-title":"Singapore Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e18028","DOI":"10.5812\/ircmj.18028","article-title":"Hydroxyurea treatment in transfusion dependent thalassaemia patients","volume":"16","author":"Bordbar","year":"2014","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2007.06654.x","article-title":"Modern treatment of thalassaemia intermedia","volume":"138","author":"Borgna-Pignatti","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000204084","article-title":"Effects of calcitonin therapy on osteoporosis in patients with thalassemia","volume":"93","author":"Akar","year":"1995","journal-title":"Acta Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormone"},{"issue":"8","key":"10.1002\/14651858.CD010429.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01955263","article-title":"Growth and development in thalassaemia major patients with bone lesion due to desferrioxamine","volume":"155","author":"De Sanctis","year":"1996","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0072|cit72","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/096228020101000502","article-title":"Statistical\u00a0methods\u00a0for the\u00a0meta-analysis\u00a0of\u00a0cluster\u00a0randomization\u00a0trials","volume":"10","author":"Donner","year":"2001","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0075|cit75","first-page":"65","article-title":"Mechanisms of action of the bisphosphonates","volume":"57 Suppl 1","year":"1997","journal-title":"Medicina (Buenos Aires)"},{"issue":"5","key":"10.1002\/14651858.CD010429.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassaemia","volume":"21","author":"Galanello","year":"2010","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03345587","article-title":"Bisphosphonates in the treatment of thalassemia-associated osteoporosis","volume":"31","author":"Gaudio","year":"2008","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0078|cit78","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0079|cit79","first-page":"975","article-title":"High incidence of\u00a0osteoporosis\u00a0in\u00a0thalassaemia\u00a0major","volume":"11","author":"Tuck","year":"1998","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.1998.01108.x","article-title":"High prevalence of low bone mass in thalassaemia major","volume":"103","author":"Jensen","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"5A","key":"10.1002\/14651858.CD010429.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/0002-9343(93)90380-8","article-title":"Hormone replacement therapy for prevention and treatment of\u00a0osteoporosis","volume":"95","author":"Lindsay","year":"1993","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0082|cit82","first-page":"297","article-title":"Zinc and copper status in children with beta-thalassemia major","volume":"20","author":"Mahyar","year":"2010","journal-title":"Iranian Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/03630269.2011.598985","article-title":"Clinicopathological and radiological study of Egyptian \u03b2-thalassemia intermedia and \u03b2-thalassemia major patients: relation to complications and response to therapy","volume":"35","author":"Mokhtar","year":"2011","journal-title":"Hemoglobin"},{"issue":"12","key":"10.1002\/14651858.CD010429.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos International"},{"issue":"1","key":"10.1002\/14651858.CD010429.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2004.04871.x","article-title":"Treatment of beta-thalassaemia-associated\u00a0osteoporosis\u00a0with zoledronic acid","volume":"125","author":"\u00a0Vyzantiadis","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0086|cit86","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010429.pub3-BIB0087|cit87","first-page":"3773","article-title":"Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients","volume":"11","author":"Ruggiero","year":"1998","journal-title":"Journal of Pediatric Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0088|cit88","first-page":"167","article-title":"Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment","volume":"11","author":"De Sanctis","year":"2013","journal-title":"Pediatric Endocrinology Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2265.2008.03191.x","article-title":"Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites","volume":"69","author":"Scacchi","year":"2008","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD010429.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/08880010701533702","article-title":"Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major","volume":"24","author":"Shamshirsaz","year":"2007","journal-title":"Pediatric Hematology and Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1359\/jbmr.1997.12.6.869","article-title":"Regulation of osteoclast function","volume":"12","author":"Suda","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos International"},{"issue":"10","key":"10.1002\/14651858.CD010429.pub3-BIB0093|cit93","first-page":"817","article-title":"Prevalence of fractures among Thais with thalassaemia syndromes","volume":"51","author":"Sutipornpalangkul","year":"2010","journal-title":"Singapore Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD010429.pub3-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009415.pub2","article-title":"Zinc supplements for treating thalassaemia and sickle cell disease","author":"Swe","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1749-6632.1998.tb10491.x","article-title":"The morbidity of bone disease in thalassaemia","volume":"850","author":"Vichinsky","year":"1998","journal-title":"Annals New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.10.001","article-title":"Prevalence of fractures among the thalassemia syndromes in North America","volume":"38","author":"Vogiatzi","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD010429.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","article-title":"New insight into the pathophysiology and management of osteoporosis in patient with beta thalassaemia","volume":"127","author":"Voskaridou","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0098|cit98","first-page":"581","volume-title":"Williams Hematology","author":"Weatherall","year":"1995"},{"key":"10.1002\/14651858.CD010429.pub3-BIB0099|cit99","unstructured":"World Health Organization Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843 whqlibdoc.who.int\/trs\/WHO_TRS_843.pdf"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2141.1998.01107.x","article-title":"Bone disease in \u03b2-thalassaemia major","volume":"103","author":"Wonke","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010429.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0037-1963(01)90029-0","article-title":"Clinical management of beta-thalassemia major","volume":"38","author":"Wonke","year":"2001","journal-title":"Seminars in Hematology"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010429.pub2","article-title":"Treatment for osteoporosis in people with \u03b2-thalassaemia","author":"Bhardwaj","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010429.pub3-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010429.pub2","article-title":"Treatment for osteoporosis in people with \u03b2-thalassaemia","author":"Bhardwaj","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:03:50Z","timestamp":1765911830000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010429.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":103,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010429.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}